KR100658489B1 - Hiv 복제를 억제하는 피리미딘 - Google Patents
Hiv 복제를 억제하는 피리미딘 Download PDFInfo
- Publication number
- KR100658489B1 KR100658489B1 KR1020017003576A KR20017003576A KR100658489B1 KR 100658489 B1 KR100658489 B1 KR 100658489B1 KR 1020017003576 A KR1020017003576 A KR 1020017003576A KR 20017003576 A KR20017003576 A KR 20017003576A KR 100658489 B1 KR100658489 B1 KR 100658489B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- alkyl
- cyano
- compound
- formula
- Prior art date
Links
- 0 CC[N+](C)(C*C)[O-] Chemical compound CC[N+](C)(C*C)[O-] 0.000 description 2
- UGKJLEKDIQDMPJ-UHFFFAOYSA-N Cc(cc(cc1C)N)c1Oc(nc(N)nc1)c1N Chemical compound Cc(cc(cc1C)N)c1Oc(nc(N)nc1)c1N UGKJLEKDIQDMPJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
Abstract
Description
Claims (20)
- 화학식(I-a)의 화합물, 그의 N-옥사이드, 약제학적으로 허용되는 부가염 또는 4급 아민:상기 식에서,-b1=b2-C(R2a)=b3-b4=은 화학식-CH=CH-C(R2a)=CH-CH= (b-1);-N=CH-C(R2a)=CH-CH= (b-2);의 2가 라디칼을 나타내며;q는 0이고;R1은 수소; 포르밀; C1-6알킬카보닐; C1-6알킬옥시카보닐; C1-6알킬옥시카보닐 또는 C1-6알킬카보닐옥시로 치환된 C1-6알킬; 또는 C1-6알킬옥시카보닐로 치환된 C1-6알킬옥시C1-6알킬카보닐이며;R2a는 시아노 또는 아미노카보닐이고;L은 -X-R3이며,여기에서,R3은 시아노, 아미노카보닐, 할로 또는 C1-6알킬 중에서 각각 독립적으로 선택된 1개, 2개 또는 3개의 치환체에 의해 치환된 페닐이고;X는 -NH, -O- 또는 S-이며;Q는 수소, C1-6알킬, 할로 또는 -NR4R5를 나타내고;R4 및 R5는 각각 독립적으로 수소, C1-6알킬, C1-6알킬옥시, 또는 피롤리디닐로 치환된 C1-6알킬로부터 선택되고;Y는 할로, 니트로, 시아노, 아미노카보닐, -NHC(=O)R6(여기에서 R6는 C1-6알킬이다), 아미노, 페닐 또는 C2-6알케닐이다.
- 제 1 항에 있어서, R1이 수소, 포르밀, C1-6알킬카보닐, C1-6알킬옥시카보닐, 또는 C1-6알킬옥시카보닐로 치환된 C1-6알킬인 화합물.
- 제 1 항에 있어서, L이 -X-R3(여기에서, R3는 2,4,6-삼치환된 페닐이다)인 화합물.
- 제 1 항에 있어서, Y가 시아노, -C(=O)NH2 또는 할로겐인 화합물.
- 제 1 항에 있어서, Q가 수소 또는 -NR4R5인 화합물.
- 제 1 항에 있어서,4-[[4-아미노-5-클로로-6-[(2,4,6-트리메틸페닐)아미노]-2-피리미디닐]아미노]벤조니트릴;4-[[5-클로로-4-[(2,4,6-트리메틸페닐)아미노]-2-피리미디닐]아미노]벤조니트릴;4-[[5-브로모-4-(4-시아노-2,6-디메틸페녹시)-2-피리미디닐]아미노]벤조니트릴;4-[[4-아미노-5-클로로-6-[(4-시아노-2,6-디메틸페닐)아미노]-2-피리미디닐]아미노]벤조니트릴;4-[[5-브로모-6-[(4-시아노-2,6-디메틸페닐)아미노]-2-피리미디닐]아미노]벤조니트릴;4-[[4-아미노-5-클로로-6-(4-시아노-2,6-디메틸페닐옥시)-2-피리미디닐]아미노]벤조니트릴; 또는4-[[4-아미노-5-브로모-6-(4-시아노-2,6-디메틸페닐옥시)-2-피리미디닐]아미노]벤조니트릴; 그의 N-옥사이드, 약제학적으로 허용되는 부가염 및 4급 아민인 화합물.
- 제 1 항 내지 제 6 항중 어느 한항에 있어서, 약제로서 사용하기 위한 화합물.
- 약제학적으로 허용되는 담체와, 화학식(I)의 화합물, 그의 N-옥사이드, 약제학적으로 허용되는 부가염 또는 4급 아민을 함유하는 HIV(인간 면역결핍 바이러스) 감염 치료용 약제학적 조성물:상기 식에서,-a1=a2-a3=a4-는 구조식-CH=CH-CH=CH- (a-1);-N=CH-CH=CH- (a-2);의 2가 라디칼을 나타내며;n은 1 또는 3이고;R1은 수소; 포르밀; C1-6알킬카보닐; C1-6알킬옥시카보닐; C1-6알킬옥시카보닐 또는 C1-6알킬카보닐옥시로 치환된 C1-6알킬; 또는 C1-6알킬옥시카보닐로 치환된 C1-6알킬옥시C1-6알킬카보닐이며;각 R2는 독립적으로 시아노, 아미노카보닐 또는 C1-6알킬이고;L은 -X-R3이며,여기에서,R3은 시아노, 아미노카보닐, 할로 또는 C1-6알킬 중에서 각각 독립적으로 선택된 1개, 2개 또는 3개의 치환체에 의해 치환된 페닐이고;X는 -NH, -O- 또는 S-이며;Q는 수소, C1-6알킬, 할로 또는 -NR4R5를 나타내고;R4 및 R5는 각각 독립적으로 수소, C1-6알킬, C1-6알킬옥시, 또는 피롤리디닐로 치환된 C1-6알킬로부터 선택되고;Y는 할로, 니트로, 시아노, 아미노카보닐, -NHC(=O)R6(여기에서 R6는 C1-6알킬이다), 아미노, 페닐 또는 C2-6알케닐이다.
- R1이 수소, 포르밀, C1-6알킬카보닐, C1-6알킬옥시카보닐, 또는 C1-6알킬옥시카보닐로 치환된 C1-6알킬인 제 1 항 내지 제 6 항 중 어느 한 항에 따른 화합물을 함유하는 HIV(인간 면역결핍 바이러스) 감염 치료용 약제학적 조성물.
- 제 1 항 내지 제 6 항중 어느 한 항에 따른 화합물을 함유하는, HIV(인간 면역결핍 바이러스) 감염 치료용 약제.
- 약제학적으로 허용되는 담체와 치료 활성량의 제 1 항 내지 제 6 항중 어느 한 항에 따른 화합물을 함유하는 HIV(인간 면역결핍 바이러스) 감염 치료용 약제학적 조성물.
- 치료 유효량의 제 1 항 내지 제 6 항중 어느 한 항에 따른 화합물을 약제학적으로 허용되는 담체와 밀접히 혼합시킴을 특징으로 하는 제 11 항에 따른 약제학적 조성물을 제조하는 방법.
- a) 화학식(II)의 중간체를 용매가 없는 조건하에서 또는 반응-불활성 용매중에서, 반응 불활성 대기하에 화학식(III)의 아미노 유도체와 반응시키거나;b) 화학식(IV)의 중간체를 용매가 없는 조건하에서 또는 적절한 용매중에서, 반응-불활성 대기하에, 화학식(V)의 중간체와 반응시키거나;c) 화학식(IV)의 중간체를 적절한 용매중에서, 반응-불활성 대기하에, 적절한 염기의 존재하에서 화학식(VI)의 중간체와 반응시키는 것을 특징으로 하는 제 1 항에 따른 화합물을 제조하는 방법:상기 식에서,W1은 할로겐, 하이드록시, 트리플레이트, 토실레이트, 티오메틸, 메틸설포닐 및 트리플루오로메틸설포닐로 구성된 그룹 중에서 선택된 이탈 그룹이고,L, Y, Q, R1, R2, R2a, R3, q 및 -b1=b2-C(R2a)=b3-b4는 제 1 항에서 정의된 바와 같으며,W2는 할로겐 또는 트리플레이트 중에서 선택된 이탈 그룹이다.
- 제 1 항 또는 제 8 항에 따른 화합물과 또다른 항-HIV 화합물의 배합물.
- 제 14 항에 있어서, 약제로서 사용하기 위한 배합물.
- (a) 제 1 항 또는 제 8 항에 따른 화합물, 및 (b) 또다른 항-HIV 화합물을 함유하는, 항-HIV 치료에서 동시에, 별개로 또는 순차적으로 사용하기 위한 배합된 제제.
- 약제학적으로 허용되는 담체 및 활성 성분으로서 (a) 제 1 항 또는 제 8항에 따른 화합물, 및 (b) 또다른 항-HIV 화합물을 함유하는 HIV(인간 면역결핍 바이러스) 감염 치료용 약제학적 조성물.
- 제1항에 있어서, 4-[[4-아미노-5-브로모-6-(4-시아노-2,6-디메틸페닐옥시)-2-피리미디닐]아미노]벤조니트릴; 그의 N-옥사이드, 약제학적으로 허용되는 부가염 또는 4급 아민인 화합물.
- 제1항에 있어서, 4-[[4-아미노-5-브로모-6-(4-시아노-2,6-디메틸페닐옥시)-2-피리미디닐]아미노]벤조니트릴인 화합물.
- 제1항에 있어서, -b1=b2-C(R2a)=b3-b4=이 화학식 (b-1)의 2가 라디칼을 나타내는 화합물.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10779298P | 1998-11-10 | 1998-11-10 | |
US60/107,792 | 1998-11-10 | ||
US14396299P | 1999-07-15 | 1999-07-15 | |
US60/143,962 | 1999-07-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010075235A KR20010075235A (ko) | 2001-08-09 |
KR100658489B1 true KR100658489B1 (ko) | 2006-12-18 |
Family
ID=26805159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017003576A KR100658489B1 (ko) | 1998-11-10 | 1999-09-24 | Hiv 복제를 억제하는 피리미딘 |
Country Status (41)
Country | Link |
---|---|
US (5) | US6878717B2 (ko) |
EP (2) | EP1002795B1 (ko) |
JP (1) | JP3635238B2 (ko) |
KR (1) | KR100658489B1 (ko) |
CN (1) | CN1214013C (ko) |
AP (1) | AP1683A (ko) |
AR (1) | AR024227A1 (ko) |
AT (2) | ATE455107T1 (ko) |
AU (2) | AU762523C (ko) |
BG (1) | BG65103B1 (ko) |
BR (1) | BRPI9915552B8 (ko) |
CA (1) | CA2350801C (ko) |
CY (1) | CY2008021I2 (ko) |
CZ (1) | CZ301367B6 (ko) |
DE (3) | DE122009000003I1 (ko) |
DK (1) | DK1002795T3 (ko) |
EA (1) | EA004049B1 (ko) |
EE (1) | EE05086B1 (ko) |
ES (2) | ES2193664T3 (ko) |
FR (1) | FR09C0004I2 (ko) |
HK (2) | HK1025330A1 (ko) |
HR (2) | HRP20010161B9 (ko) |
HU (2) | HU227453B1 (ko) |
ID (1) | ID28376A (ko) |
IL (2) | IL143023A0 (ko) |
LT (1) | LTC1002795I2 (ko) |
LU (1) | LU91528I2 (ko) |
MY (1) | MY121108A (ko) |
NL (1) | NL300373I2 (ko) |
NO (3) | NO318801B1 (ko) |
NZ (1) | NZ511116A (ko) |
OA (1) | OA11674A (ko) |
PL (1) | PL204427B1 (ko) |
PT (1) | PT1002795E (ko) |
SI (1) | SI1002795T1 (ko) |
SK (2) | SK287269B6 (ko) |
TR (1) | TR200101306T2 (ko) |
TW (1) | TWI238161B (ko) |
UA (1) | UA70966C2 (ko) |
WO (1) | WO2000027825A1 (ko) |
ZA (1) | ZA200103769B (ko) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL204427B1 (pl) * | 1998-11-10 | 2010-01-29 | Janssen Pharmaceutica Nv | Hamująca replikację wirusa HIV pochodna pirymidyny, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
IL148801A0 (en) * | 1999-09-24 | 2002-09-12 | Janssen Pharmaceutica Nv | Antiviral compositions |
DE19945982A1 (de) | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
HUP0301117A3 (en) | 2000-02-17 | 2004-01-28 | Amgen Inc Thousand Oaks | Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them |
WO2001085700A2 (en) | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
ES2559273T3 (es) | 2000-05-08 | 2016-02-11 | Janssen Pharmaceutica Nv | Profármacos de pirimidinas que inhiben la replicación del VIH |
EP1337931A4 (en) * | 2000-11-01 | 2005-05-11 | Snapnames Com Inc | DOMAIN NAME ACQUISITION AND MANAGEMENT SYSTEM AND METHOD |
US6958211B2 (en) | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
CA2463989C (en) | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
US7183288B2 (en) | 2001-11-01 | 2007-02-27 | Herwig Josephus Margareta Janssen, legal representative | Amide derivatives as glycogen synthase kinase 3-β inhibitors |
AU2002363176B2 (en) | 2001-11-01 | 2008-09-25 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors) |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
DE60326436D1 (en) | 2002-03-13 | 2009-04-16 | Janssen Pharmaceutica Nv | Aminoderivate als histone-deacetylase-inhibitoren |
BR0307599A (pt) | 2002-03-13 | 2005-02-01 | Janssen Pharmaceutica Nv | Derivados de sulfonilamino como inibidores de histona deacetilase |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
PL220850B1 (pl) * | 2002-05-03 | 2016-01-29 | Janssen Pharmaceutica Nv | Kopolimer dwublokowy, kompozycja zawierająca składnik aktywny i jej zastosowanie oraz sposób jej wytwarzania |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
AR040456A1 (es) | 2002-06-27 | 2005-04-06 | Bristol Myers Squibb Co | Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana |
DK1534286T3 (da) | 2002-07-29 | 2010-04-26 | Rigel Pharmaceuticals Inc | Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser |
MXPA05001541A (es) | 2002-08-09 | 2005-04-19 | Janssen Pharmaceutica Nv | Procedimientos para la preparacion de 4-[[4 -[[4- (2-cianoetenil)- 2, 6-dimetilfenil] amino]-2 -pirimidinil] amino] benzonitrilo. |
US7815934B2 (en) * | 2002-09-20 | 2010-10-19 | Alpharma Pharmaceuticals, Llc | Sequestering subunit and related compositions and methods |
NZ539823A (en) * | 2002-11-28 | 2008-04-30 | Schering Aktiengessellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
SG182004A1 (en) | 2003-01-14 | 2012-07-30 | Arena Pharm Inc | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
PL232814B1 (pl) * | 2003-02-07 | 2019-07-31 | Janssen Pharmaceutica Nv | Pochodne 1,2,4-triazynowe, ich zastosowanie i zawierająca je kompozycja farmaceutyczna |
WO2004069812A1 (en) | 2003-02-07 | 2004-08-19 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of hiv infection |
US7514446B2 (en) | 2003-02-20 | 2009-04-07 | Smithkline Beecham Corporation | Pyrimidine compounds |
CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
BRPI0412734A (pt) * | 2003-07-17 | 2006-09-26 | Tibotec Pharm Ltd | processo para preparação de partìculas que contêm um antiviral |
PT1656372E (pt) | 2003-07-30 | 2013-06-27 | Rigel Pharmaceuticals Inc | Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina |
DE602004031641D1 (de) * | 2003-09-25 | 2011-04-14 | Janssen Pharmaceutica Nv | Die replikation von hiv hemmende purinderivate |
WO2005086061A2 (en) | 2004-03-02 | 2005-09-15 | Virco Bvba | Estimation of clinical cut-offs |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
PL1781639T3 (pl) | 2004-07-28 | 2012-07-31 | Janssen Pharmaceutica Nv | Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej |
AU2005271161B2 (en) | 2004-08-10 | 2011-05-12 | Janssen Pharmaceutica N.V. | HIV inhibiting 1,2,4-triazin-6-one derivatives |
WO2006035069A1 (en) * | 2004-09-30 | 2006-04-06 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-substituted pyrimidines |
ES2371924T3 (es) | 2004-09-30 | 2012-01-11 | Tibotec Pharmaceuticals | Pirimidinas 5-carbo o heterociclo- sustituidas que inhiben el hiv. |
AU2005288864B2 (en) | 2004-09-30 | 2012-08-23 | Janssen Sciences Ireland Uc | HIV inhibiting 5-heterocyclyl pyrimidines |
JP5118972B2 (ja) | 2004-10-29 | 2013-01-16 | テイボテク・フアーマシユーチカルズ | Hiv阻害性二環式ピリミジン誘導体 |
CA2583187A1 (en) * | 2004-11-08 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and etravirine |
US7557207B2 (en) | 2004-11-24 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
AU2006208778B2 (en) | 2005-01-27 | 2012-08-09 | Janssen Sciences Ireland Uc | HIV inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives |
DE602006001515D1 (de) | 2005-02-16 | 2008-07-31 | Astrazeneca Ab | Chemische verbindungen |
WO2006087387A1 (en) * | 2005-02-18 | 2006-08-24 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives |
MX2007010744A (es) * | 2005-03-04 | 2007-09-12 | Tibotec Pharm Ltd | 2-(4-cianofenil)-6-hidroxilaminopirimidas que inhiben el virus de inmunodeficiencia humana. |
US20080287437A1 (en) | 2005-05-16 | 2008-11-20 | Astrazeneca Ab | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors |
CN101248051B (zh) * | 2005-05-26 | 2013-07-17 | 泰博特克药品有限公司 | 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法 |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP1945208A4 (en) * | 2005-10-06 | 2011-08-03 | Univ Massachusetts | COMPOSITION AND SYNTHESIS OF NEW REAGENTS TO INHIBIT HIV REPLICATION |
US20080287475A1 (en) | 2005-10-28 | 2008-11-20 | Astrazeneca Ab | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer |
DE602007001190D1 (de) | 2006-01-19 | 2009-07-09 | Janssen Pharmaceutica Nv | Aminophenylderivate als neue inhibitoren von histondeacetylase |
US8114876B2 (en) | 2006-01-19 | 2012-02-14 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
DK1981875T3 (da) | 2006-01-19 | 2014-07-14 | Janssen Pharmaceutica Nv | Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase |
ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
US8933089B2 (en) | 2006-03-30 | 2015-01-13 | Janssen R & D Ireland | HIV inhibiting 5-amido substituted pyrimidines |
DE602007009508D1 (de) | 2006-03-30 | 2010-11-11 | Little Island Co Cork | Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine |
PE20120006A1 (es) | 2006-05-15 | 2012-02-02 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
ES2372983T3 (es) | 2006-06-06 | 2012-01-30 | Tibotec Pharmaceuticals | Proceso para preparar formulaciones secadas por aspersión de tmc125. |
HUE032156T2 (en) | 2006-06-19 | 2017-09-28 | Alpharma Pharmaceuticals Llc | Pharmaceutical preparations |
US20080233156A1 (en) * | 2006-10-11 | 2008-09-25 | Alpharma, Inc. | Pharmaceutical compositions |
US20100041687A1 (en) | 2006-12-06 | 2010-02-18 | Thone Daniel Joseph Christiaan | Hydrobromide salt of an anti-hiv compound |
CN101573343B (zh) * | 2006-12-29 | 2016-02-24 | 爱尔兰詹森科学公司 | 抑制人免疫缺陷病毒的6-取代的嘧啶 |
AU2007341228B2 (en) | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
WO2009051782A1 (en) * | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US20090196890A1 (en) * | 2007-12-17 | 2009-08-06 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
SI2300013T1 (en) | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
DK2361248T3 (en) | 2008-06-27 | 2019-01-14 | Celgene Car Llc | Heteroberl compounds and uses thereof |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US20100137313A1 (en) * | 2008-10-03 | 2010-06-03 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
BRPI1012666B8 (pt) | 2009-03-30 | 2021-05-25 | Janssen R&D Ireland | cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso |
ES2659725T3 (es) | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | Inhibidores de EGFR y procedimiento de tratamiento de trastornos |
WO2010131118A2 (en) * | 2009-05-12 | 2010-11-18 | Pliva Hrvatska D.O.O. | Polymorphs of etravirine and processes for preparation thereof |
AP2858A (en) | 2009-06-22 | 2014-02-28 | Emcure Pharmaceuticals Ltd | Process for synthesis of a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor |
WO2011017079A1 (en) | 2009-07-27 | 2011-02-10 | Teva Pharmaceutical Industries Ltd. | Process for the preparation and purification of etravirine and intermediates thereof |
GR1007010B (el) | 2009-10-08 | 2010-10-07 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Ινσουλινοειδη πεπτιδια |
US8354420B2 (en) | 2010-06-04 | 2013-01-15 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 inhibitors |
WO2012001695A1 (en) | 2010-06-28 | 2012-01-05 | Hetero Research Foundation | A process for etra virine intermediate and polymorphs of etravirine |
EP3144298A1 (en) | 2010-08-10 | 2017-03-22 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
MX2013004894A (es) | 2010-11-01 | 2013-10-17 | Celgene Avilomics Res Inc | Compuestos heterociclicos y usos de los mismos. |
PT3124483T (pt) | 2010-11-10 | 2019-10-02 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2 |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
ES2655525T3 (es) | 2011-04-26 | 2018-02-20 | Mylan Laboratories Ltd. | Proceso novedoso para la preparación de Etravirina |
JP5999177B2 (ja) | 2011-05-04 | 2016-09-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
WO2012170647A1 (en) * | 2011-06-09 | 2012-12-13 | Assia Chemical Industriew Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
JP5993010B2 (ja) | 2011-08-23 | 2016-09-14 | エンドゥ ファーマシューティカルズ,インコーポレイティド | ピリミド−ピリダジノン化合物及びその使用 |
WO2013059572A1 (en) | 2011-10-19 | 2013-04-25 | Assia Chemical Industries Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
AR088570A1 (es) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
US8703786B2 (en) * | 2011-12-07 | 2014-04-22 | Texas Southern University | Etravirine formulations and uses thereof |
MX356179B (es) | 2012-03-15 | 2018-05-17 | Celgene Avilomics Res Inc | Sales de un inhibidor de cinasa del receptor del factor de crecimiento epidermico. |
JP6317319B2 (ja) | 2012-03-15 | 2018-04-25 | セルジーン シーエーアール エルエルシー | 上皮成長因子受容体キナーゼ阻害剤の固体形態 |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
US20150336900A1 (en) * | 2012-10-29 | 2015-11-26 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the Synthesis of Etravirine and Its Intermediates |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
EP2935226A4 (en) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | HETEROARYL COMPOUNDS AND USES THEREOF |
CN104968340A (zh) | 2012-12-21 | 2015-10-07 | 沃利克斯制药股份有限公司 | 治疗肝脏疾病或病状的用途和方法 |
CN105188371A (zh) | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
ES2741785T3 (es) | 2014-08-13 | 2020-02-12 | Celgene Car Llc | Formas y composiciones de un inhibidor de ERK |
MX2017008925A (es) | 2015-01-06 | 2017-10-11 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
CN104926829A (zh) * | 2015-06-08 | 2015-09-23 | 山东大学 | 一种噻吩并嘧啶类衍生物及其制备方法和应用 |
KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염 |
CN110066273A (zh) * | 2019-06-05 | 2019-07-30 | 山东大学 | 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用 |
CA3145864A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
CN111217833B (zh) * | 2020-02-21 | 2021-03-16 | 山东大学 | 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用 |
CN111875548A (zh) * | 2020-07-16 | 2020-11-03 | 山东大学 | 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US4659363A (en) * | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
ATE60591T1 (de) * | 1984-06-25 | 1991-02-15 | Ciba Geigy Ag | Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel. |
ZA892407B (en) | 1988-03-31 | 1989-11-29 | Mitsubishi Chem Ind | 6-substituted acyclopyrimidine nucleoside derivative and antiviral agent containing the same as active ingredient thereof |
JPH02308248A (ja) | 1989-05-24 | 1990-12-21 | Fuji Photo Film Co Ltd | アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料 |
JP2895680B2 (ja) * | 1992-07-08 | 1999-05-24 | シャープ株式会社 | 磁気ヘッドおよびその製造方法 |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
TR199800729T2 (xx) | 1995-11-23 | 1998-07-21 | Janssen Pharmaceutica N.V. | Eritmeli ekstr�zyonla haz�rlanan siklodekstrin kat� kar���mlar�. |
KR100219922B1 (ko) * | 1996-05-16 | 1999-09-01 | 이서봉 | 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법 |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
DE29704863U1 (de) * | 1997-03-17 | 1997-05-22 | Ges Innenhochdruckverfahren | Achsschwinge |
EA200000840A1 (ru) | 1998-02-17 | 2001-02-26 | Туларик, Инк. | Антивирусные производные пиримидина |
DE69943247D1 (de) * | 1998-03-27 | 2011-04-14 | Janssen Pharmaceutica Nv | HIV hemmende Pyrimidin Derivate |
EP0945443B9 (en) * | 1998-03-27 | 2003-08-13 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
EP0945442A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted pyrimidine derivatives |
PL204427B1 (pl) * | 1998-11-10 | 2010-01-29 | Janssen Pharmaceutica Nv | Hamująca replikację wirusa HIV pochodna pirymidyny, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna |
ES2559273T3 (es) * | 2000-05-08 | 2016-02-11 | Janssen Pharmaceutica Nv | Profármacos de pirimidinas que inhiben la replicación del VIH |
-
1999
- 1999-09-24 PL PL347586A patent/PL204427B1/pl unknown
- 1999-09-24 CZ CZ20011533A patent/CZ301367B6/cs not_active IP Right Cessation
- 1999-09-24 WO PCT/EP1999/007417 patent/WO2000027825A1/en active Application Filing
- 1999-09-24 AP APAP/P/2001/002121A patent/AP1683A/en active
- 1999-09-24 AU AU62008/99A patent/AU762523C/en not_active Revoked
- 1999-09-24 TR TR2001/01306T patent/TR200101306T2/xx unknown
- 1999-09-24 KR KR1020017003576A patent/KR100658489B1/ko active IP Right Grant
- 1999-09-24 IL IL14302399A patent/IL143023A0/xx active Protection Beyond IP Right Term
- 1999-09-24 CN CNB998119180A patent/CN1214013C/zh not_active Expired - Lifetime
- 1999-09-24 CA CA002350801A patent/CA2350801C/en not_active Expired - Lifetime
- 1999-09-24 NZ NZ511116A patent/NZ511116A/en not_active IP Right Cessation
- 1999-09-24 HU HU0104177A patent/HU227453B1/hu active Protection Beyond IP Right Term
- 1999-09-24 SK SK603-2001A patent/SK287269B6/sk active Protection Beyond IP Right Term
- 1999-09-24 EA EA200100536A patent/EA004049B1/ru active IP Right Revival
- 1999-09-24 OA OA1200100113A patent/OA11674A/en unknown
- 1999-09-24 UA UA2001042857A patent/UA70966C2/uk unknown
- 1999-09-24 ID IDW00200101015A patent/ID28376A/id unknown
- 1999-09-24 SK SK5012-2009A patent/SK287270B6/sk not_active IP Right Cessation
- 1999-09-24 JP JP2000581005A patent/JP3635238B2/ja not_active Expired - Lifetime
- 1999-09-24 BR BRPI9915552A patent/BRPI9915552B8/pt not_active IP Right Cessation
- 1999-09-24 HU HU1100091A patent/HU230394B1/hu unknown
- 1999-09-24 EE EEP200100252A patent/EE05086B1/xx active Protection Beyond IP Right Term
- 1999-11-01 DE DE122009000003C patent/DE122009000003I1/de active Pending
- 1999-11-01 DE DE69941934T patent/DE69941934D1/de not_active Expired - Lifetime
- 1999-11-01 DK DK99203590T patent/DK1002795T3/da active
- 1999-11-01 SI SI9930275T patent/SI1002795T1/xx unknown
- 1999-11-01 PT PT99203590T patent/PT1002795E/pt unknown
- 1999-11-01 ES ES99203590T patent/ES2193664T3/es not_active Expired - Lifetime
- 1999-11-01 US US09/430,966 patent/US6878717B2/en not_active Expired - Lifetime
- 1999-11-01 EP EP99203590A patent/EP1002795B1/en not_active Expired - Lifetime
- 1999-11-01 ES ES02018455T patent/ES2338760T3/es not_active Expired - Lifetime
- 1999-11-01 AT AT02018455T patent/ATE455107T1/de not_active IP Right Cessation
- 1999-11-01 AT AT99203590T patent/ATE233740T1/de active
- 1999-11-01 EP EP02018455A patent/EP1270560B1/en not_active Expired - Lifetime
- 1999-11-01 DE DE69905683T patent/DE69905683T2/de not_active Expired - Lifetime
- 1999-11-05 MY MYPI99004805A patent/MY121108A/en unknown
- 1999-11-09 AR ARP990105680A patent/AR024227A1/es active IP Right Grant
- 1999-12-23 TW TW088119614A patent/TWI238161B/zh not_active IP Right Cessation
-
2000
- 2000-07-26 HK HK00104633A patent/HK1025330A1/xx not_active IP Right Cessation
-
2001
- 2001-03-07 HR HRP20010161AA patent/HRP20010161B9/hr not_active IP Right Cessation
- 2001-04-04 NO NO20011696A patent/NO318801B1/no not_active IP Right Cessation
- 2001-04-06 BG BG105418A patent/BG65103B1/bg unknown
- 2001-05-09 ZA ZA200103769A patent/ZA200103769B/en unknown
-
2003
- 2003-02-14 HK HK03101063.7A patent/HK1048817B/zh not_active IP Right Cessation
- 2003-08-05 US US10/634,682 patent/US7037917B2/en not_active Expired - Lifetime
-
2005
- 2005-07-28 IL IL169949A patent/IL169949A/en not_active IP Right Cessation
- 2005-08-16 US US11/204,513 patent/US20050288278A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/930,835 patent/US8003789B2/en not_active Expired - Fee Related
-
2008
- 2008-07-17 HR HRP20080359AA patent/HRP20080359B1/hr not_active IP Right Cessation
- 2008-12-03 LT LTPA2008016C patent/LTC1002795I2/lt unknown
- 2008-12-10 CY CY2008021C patent/CY2008021I2/el unknown
-
2009
- 2009-01-13 NL NL300373C patent/NL300373I2/nl unknown
- 2009-01-22 FR FR09C0004C patent/FR09C0004I2/fr active Active
- 2009-02-18 LU LU91528C patent/LU91528I2/fr unknown
- 2009-02-23 NO NO2009003C patent/NO2009003I2/no unknown
-
2011
- 2011-02-18 AU AU2011200708A patent/AU2011200708A1/en active Pending
- 2011-07-06 US US13/177,188 patent/US8530655B2/en not_active Expired - Fee Related
-
2021
- 2021-03-29 NO NO2021015C patent/NO2021015I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100658489B1 (ko) | Hiv 복제를 억제하는 피리미딘 | |
EP1282606B1 (en) | Hiv replication inhibiting pyrimidines and triazines | |
DK1282607T3 (en) | Prodrugs of HIV replication inhibiting pyrimidines | |
EP1419152B1 (en) | Hiv inhibiting pyrimidines derivatives | |
EP1225874B1 (en) | Antiviral solid dispersions | |
EP1129079B1 (en) | 2,4-disubstituded triazine derivatives with anti hiv activity | |
MXPA01003646A (en) | Hiv replication inhibiting pyrimidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121122 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131119 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141120 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151118 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171117 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181115 Year of fee payment: 13 |